[Federal Register Volume 72, Number 45 (Thursday, March 8, 2007)]
[Rules and Regulations]
[Pages 10357-10358]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-4100]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 558


New Animal Drugs for Use in Animal Feeds; Melengestrol, 
Ractopamine, and Monensin

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect approval of an abbreviated new animal drug 
application (ANADA) filed by Ivy Laboratories, Division of Ivy Animal 
Health, Inc. The ANADA provides for use of single-ingredient Type A 
medicated articles containing melengestrol, ractopamine, and monensin 
to make three-way combination drug Type C medicated feeds for heifers 
fed in confinement for slaughter.

DATES: This rule is effective March 8, 2007.

FOR FURTHER INFORMATION CONTACT: John K. Harshman, Center for 
Veterinary Medicine (HFV-104), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 301-827-0169, e-mail: 
[email protected].

SUPPLEMENTARY INFORMATION: Ivy Laboratories, Division of Ivy Animal 
Health, Inc., 8857 Bond St., Overland Park, KS 66214, filed ANADA 200-
448 for use of HEIFERMAX 500 (melengestrol acetate) Liquid Premix, 
OPTAFLEXX (ractopamine hydrochloride), and RUMENSIN (monensin sodium) 
single-ingredient Type A medicated article to make dry and liquid, 
three-way combination drug Type C medicated feeds for heifers fed

[[Page 10358]]

in confinement for slaughter. Ivy Laboratories' ANADA 200-448 is 
approved as a generic copy of Elanco Animal Health's NADA 141-234 for 
combination feed use of MGA 500, OPTAFLEXX, and RUMENSIN. The 
application is approved as of January 29, 2007, and the regulations are 
amended in 21 CFR 558.500 to reflect the approval. The basis of 
approval is discussed in the freedom of information summary.
    In accordance with the freedom of information provisions of 21 CFR 
part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and 
effectiveness data and information submitted to support approval of 
this application may be seen in the Division of Dockets Management 
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
    The agency has determined under 21 CFR 25.33(a)(2) that this action 
is of a type that does not individually or cumulatively have a 
significant effect on the human environment. Therefore, neither an 
environmental assessment nor an environmental impact statement is 
required.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 558

    Animal drugs, Animal feeds.

0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is 
amended as follows:

PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

0
1. The authority citation for 21 CFR part 558 continues to read as 
follows:

    Authority: 21 U.S.C. 360b, 371.


Sec.  558.500  [Amended]

0
2. In the table in paragraph (e)(2)(viii) of Sec.  558.500, in the 
``Limitations'' column remove ``No. 000009'' and add in its place 
``Nos. 000009 or 021641'', and in the ``Sponsor'' column add in 
numerical sequence ``021641''.

    Dated: February 20, 2007.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. E7-4100 Filed 3-7-07; 8:45 am]
BILLING CODE 4160-01-S